---
title: "Saroglitazar in Primary biliary cholangitis: Terms and abbreviations"
description: "Formulary evidence on Saroglitazar in Primary biliary cholangitis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Saroglitazar in Primary biliary cholangitis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 1L | First-line treatment |
| 2L+ | Second-line or later treatment |
| 5-D | Five-dimensional itch scale |
| AASLD | American Association for the Study of Liver Diseases |
| AHFS | American Hospital Formulary Service |
| AISF | Associazione Italiana per lo Studio del Fegato |
| ALP | Alkaline phosphatase |
| ALT | Alanine aminotransferase |
| AMA | Antimitochondrial antibody |
| ASP | Average sales price |
| AUC | Area under the concentration-time curve |
| CAS | Chemical Abstracts Service |
| CI | Confidence interval |
| Cmax | Maximum plasma concentration |
| DDI | Drug-drug interaction |
| EASL | European Association for the Study of the Liver |
| EC50 | Half-maximal effective concentration |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| GGT | Gamma-glutamyl transferase |
| HI | Hepatic impairment |
| hPPAR | Human peroxisome proliferator-activated receptor |
| IBAT | Ileal bile acid transporter |
| IP | Inpatient |
| MASH | Metabolic dysfunction-associated steatohepatitis |
| MASLD | Metabolic dysfunction-associated steatotic liver disease |
| MSP | Moderate-to-severe pruritus |
| NDA | New Drug Application |
| NHS | National Health System |
| NMA | Network meta-analysis |
| NMP | No or mild pruritus |
| NRS | Numerical rating scale |
| OCA | Obeticholic acid |
| PBC | Primary biliary cholangitis |
| PBC-40 | 40-item primary biliary cholangitis questionnaire |
| PDUFA | Prescription Drug User Fee Act |
| PK | Pharmacokinetics |
| PPAR | Peroxisome proliferator-activated receptor |
| QALY | Quality-adjusted life-year |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| UDCA | Ursodeoxycholic acid |
| ULN | Upper limit of normal |
| WAC | Wholesale acquisition cost |

## Related pages
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis.md)
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary.md)
- [Saroglitazar in Primary biliary cholangitis: Product information and disease description](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description.md)
- [Saroglitazar in Primary biliary cholangitis: Clinical evidence](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence.md)
- [Saroglitazar in Primary biliary cholangitis: Economic information and modeling report](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics.md)
- [Saroglitazar in Primary biliary cholangitis: References](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references.md)
- [Saroglitazar in Primary biliary cholangitis: prevalence by geography](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence.md)
- [Saroglitazar in Primary biliary cholangitis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses.md)
